Medicus Pharma (MDCX) vs Traws Pharma (TRAW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Traws Pharma is the larger company by market cap ($7.4 million vs $7.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDCX | TRAW |
|---|---|---|
| Share price | $0.1019 | $0.4803 |
| Market cap | $7.31M | $7.38M |
| 1-day change | -36.39% | +0.27% |
| YTD return | -93.34% | — |
| 1-year return | -95.86% | — |
| EPS (TTM) | $-2.38 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.78 | $3.27 |
| 52-week low | $0.0941 | $0.43 |
| Distance from 52-week high | -96.33% | -85.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +4316.09% | +108.20% |
| Average volume | 4.43M | 569.02K |
| Shares outstanding | 71.71M | 15.37M |
| Employees | 16 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Healthcare · Drug Manufacturers - General · 16 employees
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Healthcare · Biotechnology · 4 employees
MDCX vs TRAW FAQ
Which is bigger, Medicus Pharma or Traws Pharma?
Traws Pharma (TRAW) is larger, with a market capitalization of $7.38M compared with $7.31M for Medicus Pharma (MDCX).
Are Medicus Pharma and Traws Pharma in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - General for Medicus Pharma and Biotechnology for Traws Pharma.